Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
Geller
J
J
Mercy Hospital and Medical Center, San Diego, California.
Kirchenbaum
A
A
Lepor
H
H
Levine
A C
AC
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D042944:Cholestenone 5 alpha-Reductase; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery*; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin
D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D018120:Finasteride; C041226:Terazosin; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase; D016729:Leuprolide; D000077409:Tamsulosin; D011224:Prazosin